DNA Methylation Status of PAX1 and ZNF582 in Esophageal Squamous Cell Carcinoma

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2017 Mar 1

PMID 28241446

Citations 20

Authors

Jin Huang

Guo Wang

Jie Tang

Wei Zhuang

Li-Ping Wang

Yu-Ligh Liou

Ying-Zi Liu

Hong-Hao Zhou

Yuan-Shan Zhu

Affiliations

Soon will be listed here.

Abstract

Hypermethylation of specific gene promoters is an important mechanism of carcinogenesis. A high frequency of promoter methylation of and genes has been detected in cervical cancer. In the present study, we investigated the methylation status of and genes in esophageal squamous cell carcinoma (ESCC) tissues. Tumor and paracancerous tissues were obtained from 14 ESCC patients. Genomic DNA was extracted from both tumor and paracancerous tissues, and the concentration of DNA were determined. DNA methylation analysis of and genes was carried out using quantitative methylation-specific PCR. To assess the diagnostic performance of the two methylated genes for cancer detection, receiver operating characteristic (ROC) curves were generated. Sensitivities and specificities were tested at cut-offs obtained from the ROC curves. The methylation levels of both and genes were significantly higher in tumor tissues compared to non-tumor paracancerous tissues. The methylation rates of and in ESCC tumor and paracancerous tissues were 100% and 21.4% ( = 0.006), 85.7% and 0% ( < 0.001), respectively. The sensitivities and specificities of and methylation for the detection of cancer were 100% and 85.7%, and 78.6% and 100%, respectively. The DNA methylation levels and frequencies of and genes were markedly higher in ESCC tumor tissues compared to those in paracancerous tissues. Moreover, the conclusions were verified by using The Cancer Genome Atlas (TCGA) datasets. DNA methylation status of these two genes showed a relatively good sensitivity and specificity for the detection of ESCC tumors. This data suggests that DNA methylation testing holds a great promise for ESCC screening and warrants further prospective population-based studies.

Citing Articles

Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma and its Clinical Implications in Systemic Chemotherapy.

Li Z, Chen X, Li Y, Xu Y, Zhou Y Int J Med Sci. 2025; 22(4):1002-1014.

PMID: 39991775 PMC: 11843145. DOI: 10.7150/ijms.109161.

High methylation of the same promoter of lncRNA / promotes malignant progression of esophageal cancer.

Li Z, Yan H, Wang B, Wang H, Chen A, Zhu T Epigenomics. 2024; 16(10):733-752.

PMID: 38869483 PMC: 11318746. DOI: 10.1080/17501911.2024.2342229.

DNA methylation markers in esophageal cancer.

Xu Y, Wang Z, Pei B, Wang J, Xue Y, Zhao G Front Genet. 2024; 15:1354195.

PMID: 38774285 PMC: 11106492. DOI: 10.3389/fgene.2024.1354195.

Promising predictive molecular biomarkers for cervical cancer (Review).

Lizano M, Carrillo-Garcia A, De La Cruz-Hernandez E, Castro-Munoz L, Contreras-Paredes A Int J Mol Med. 2024; 53(6).

PMID: 38606495 PMC: 11090266. DOI: 10.3892/ijmm.2024.5374.

Identifying potential DNA methylation markers for the detection of esophageal cancer in plasma.

Pei B, Zhao G, Geng Z, Wang Y, Wang M, Wang X Front Genet. 2023; 14:1222617.

PMID: 37867599 PMC: 10586502. DOI: 10.3389/fgene.2023.1222617.

References

Benaglia T, Sharples L, Fitzgerald R, Lyratzopoulos G . Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology. 2012; 144(1):62-73.e6. DOI: 10.1053/j.gastro.2012.09.060. View

Li J, Ying J, Wang X, Wang Z, Tao Q, Li L . Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma. Chin J Cancer. 2012; 32(1):3-11. PMC: 3845589. DOI: 10.5732/cjc.011.10381. View

Long C, Yin B, Lu Q, Zhou X, Hu J, Yang Y . Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007; 25(8):685-90. DOI: 10.1080/07357900701561131. View

Kuo I, Chang J, Jiang S, Chen C, Chang I, Sheu B . Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. Int J Med Sci. 2014; 11(8):779-87. PMC: 4057483. DOI: 10.7150/ijms.7405. View

Huang R, Chang C, Su P, Chen Y, Liao Y, Wang H . Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS One. 2012; 7(7):e41060. PMC: 3397950. DOI: 10.1371/journal.pone.0041060. View

Guo M, Ren J, House M, Qi Y, Brock M, Herman J . Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006; 12(15):4515-22. DOI: 10.1158/1078-0432.CCR-05-2858. View

Juo Y, Johnston F, Zhang D, Juo H, Wang H, Pappou E . Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014; 25(12):2314-2327. PMC: 4239805. DOI: 10.1093/annonc/mdu149. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M . Genetic alterations in esophageal cancer. Surg Today. 2004; 35(1):7-18. DOI: 10.1007/s00595-004-2885-3. View

10.

Si H, Tsao S, Lam K, Srivastava G, Liu Y, Wong Y . E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett. 2001; 173(1):71-8. DOI: 10.1016/s0304-3835(01)00646-2. View

11.

Lang D, Powell S, Plummer R, Young K, Ruggeri B . PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2006; 73(1):1-14. DOI: 10.1016/j.bcp.2006.06.024. View

12.

Huang T, Lai H, Liu H, Lin C, Wang K, Ding D . Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer. 2010; 20(4):513-9. DOI: 10.1111/IGC.0b013e3181c7fe6e. View

13.

Kadri S, Lao-Sirieix P, Fitzgerald R . Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med. 2011; 5(3):397-404. DOI: 10.2217/bmm.11.40. View

14.

Zhang X, Yang X, Wang J, Liang T, Gu Y, Yang D . Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer. Int J Clin Exp Pathol. 2015; 8(9):11452-7. PMC: 4637690. View

15.

Robson E, He S, Eccles M . A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006; 6(1):52-62. DOI: 10.1038/nrc1778. View

16.

Chang C, Huang R, Wang H, Liao Y, Yu M, Lai H . High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma. Int J Gynecol Cancer. 2014; 24(2):201-9. DOI: 10.1097/IGC.0000000000000054. View

17.

Huang Y, Peng B, Wu C, Su C, Wang H, Lai H . DNA methylation of PAX1 as a biomarker for oral squamous cell carcinoma. Clin Oral Investig. 2013; 18(3):801-8. DOI: 10.1007/s00784-013-1048-6. View

18.

Ito S, Ohga T, Saeki H, Nakamura T, Watanabe M, Tanaka S . p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. Int J Cancer. 2004; 113(1):22-8. DOI: 10.1002/ijc.20500. View

19.

Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M . Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res. 2003; 9(4):1441-5. View

20.

Galindo R, Allport J, Olson E . A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci U S A. 2006; 103(36):13439-44. PMC: 1569182. DOI: 10.1073/pnas.0605926103. View